Improving the therapeutic index of systemic therapy with special emphasis on cisplatin and carboplatin.
Carter
S K
SK
Bristol-Myers Co., Pharmaceutical Research and Development Division, Wallingford, Connecticut.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D016190:Carboplatin; D002945:Cisplatin